Find Academic Supervisors

Patricia Champion is a Professor in the Department of Biological Sciences at the University of Notre Dame, where she holds the title of Notre Dame Collegiate Professor. Her research is centered on the molecular mechanisms of mycobacterial pathogenesis, with a focus on protein transport and virulence. She is affiliated with the Eck Institute for Global Health and the Center for Rare and Neglected Diseases. PhD in Molecular Biology, Princeton University (2003) B.S. in Biological Sciences, Carnegie Mellon University (1998) Her research interests lie in understanding how pathogenic mycobacteria, including Mycobacterium tuberculosis and M. marinum , cause disease through targeted protein secretion, particularly via the Type VII (ESX-1) secretion system. She investigates how secreted proteins function as effectors and regulate gene expression, and how post-translational modifications like acetylation influence virulence. Her lab employs an interdisciplinary approach combining genetics, molecular biology, proteomics, and transcriptomics. The recent publications highlight a strong focus on ESX-1-mediated secretion, identification of novel substrates, regulatory mechanisms (e.g., WhiB6, EspM), and post-translational modifications. The work spans fundamental bacterial physiology to host-pathogen interactions, contributing to the broader goal of identifying targets for anti-virulence therapeutics against tuberculosis. Her scientific recognition includes being named a Notre Dame Collegiate Professor, a distinguished honor reflecting her scholarly excellence. Dr. Champion leads an active research laboratory committed to fostering an inclusive and respectful environment, emphasizing core values such as integrity, teamwork, and excellence. Her lab's work is supported by ongoing research grants, though specific funding sources are not detailed in the text. The Champion Lab operates within the Department of Biological Sciences and collaborates with key institutes at Notre Dame focused on global and neglected diseases.

• Molecular Genetics
• Mycobacterial Pathogenesis
• Bacterial Genetics
• +7 more

Brian Hie is an Assistant Professor of Chemical Engineering at Stanford University , a Dieter Schwarz Foundation Stanford Data Science Faculty Fellow , and an Innovation Investigator at Arc Institute . He leads the Laboratory of Evolutionary Design , focusing on the intersection of biology and machine learning . His prior roles include a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI . Education: Ph.D. , Electrical Engineering and Computer Science , Massachusetts Institute of Technology (2021) Bachelor’s Degree , Stanford University Research Interests: Brian’s work bridges machine learning and computational biology , with a focus on protein engineering , single-cell RNA sequencing , and viral evolution . His Evolutionary velocity framework predicts protein evolutionary dynamics across timescales, while his Scanorama algorithm enables efficient integration of heterogeneous single-cell datasets. He also develops structure-informed language models for antibody optimization and uncertainty-aware ML for biological discovery. Publication Trends: His recent work (2023) emphasizes structure-based inverse folding for antibody evolution, evolutionary scale modeling , and unsupervised optimization . Earlier studies (2022-2021) cover evolutionary velocity , multi-modal single-cell analysis , and viral escape prediction using natural language analogies. Scientific Awards: Stanford Science Fellow (2021) National Defense Science and Engineering Graduate Fellowship (2019) Advising: He mentors doctoral students including Brandon Ameglio , Garyk Brixi , and Chang M. Yun , with a focus on biological design and computational methods . Labs & Collaborations: His lab collaborates with Bio-X and the Institute for Human-Centered Artificial Intelligence (HAI) , and he maintains affiliations with Sarafan ChEM-H and Stanford Data Science .

• Machine Learning
• Computational Biology
• Protein Engineering
• +6 more

Jeff Schorey is the George B. Craig Jr. Professor and a full Professor in the Department of Biological Sciences at the University of Notre Dame, where he has been a faculty member since 2004. He currently serves as Director of the Integrated Biomedical Sciences (IBMS) graduate program and previously held leadership roles including Chair of the Institutional Animal Care and Use Committee (IACUC) and Associate Director of the Eck Institute for Global Health. His research focuses on the pathobiology of mycobacterial diseases, particularly Mycobacterium tuberculosis and M. avium . His work investigates the molecular interactions between mycobacteria and host macrophages, with a special emphasis on the role of exosomes in immune modulation, diagnostics, and vaccine development. He also explores novel antibiotic development in collaboration with chemists at Notre Dame and global partners. His recent publications reveal a strong trend in extracellular vesicle biology, host-pathogen signaling, and translational applications in TB diagnostics and treatment. The articles span immunology, microbiology, and molecular biology, with recurring themes in exosome function, RNA sensing, and antimicrobial development. George B. Craig Jr. Collegiate Professor Dr. Schorey has advised graduate students and leads an active research lab focused on mycobacterial pathogenesis. His work is supported by collaborations across disciplines and institutions, particularly in drug development and clinical translation. He has contributed significantly to understanding how exosomes can serve as both biomarkers and therapeutic tools. His lab employs cellular immunology, animal models, and clinical sample analysis to study mycobacterial infections. He leads the IBMS program, shaping graduate education in biomedical sciences at Notre Dame.

• Microbiology
• Immunology
• Infectious Diseases
• +9 more

Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.

• Tuberculosis
• Antibiotic Resistance
• Metabolomics
• +3 more

Balázs Rada is an Associate Professor in the Department of Infectious Diseases at the University of Georgia's College of Veterinary Medicine. His research focuses on mechanisms of respiratory innate immunity, particularly in cystic fibrosis lung disease and host-pathogen interactions involving pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, and influenza virus. Key projects include investigating neutrophil biology, reactive oxygen species in airway defenses, and therapeutic modulation of innate immunity. His lab, the Rada Laboratory, is based in Athens, Georgia, and emphasizes translational research in respiratory disease pathogenesis. Research interests span cystic fibrosis airway inflammation, antimicrobial therapies, and the role of neutrophil extracellular traps (NETs) in lung diseases. Collaborative efforts aim to develop novel treatments targeting innate immune dysfunction.

• Infectious Diseases
• Immunology
• Bacteriology
• +7 more

Shama D Ahuja is an Adjunct Assistant Professor of Epidemiology at Columbia University Mailman School of Public Health and currently serves as Assistant Commissioner of the Bureau of Communicable Diseases at the New York City Department of Health and Mental Hygiene. Her research focuses on infectious disease transmission dynamics, molecular epidemiology, and public health interventions for vulnerable populations. She oversees surveillance and outbreak response for over 70 infectious diseases, with expertise in tuberculosis control and emerging threats like SARS-CoV-2. Dr. Ahuja holds a BS from Emory University, an MPH from Emory’s Rollins School of Public Health, and a PhD from Johns Hopkins Bloomberg School of Public Health. She has held leadership roles in organizations such as the Council for State and Territorial Epidemiologists and the Society for Epidemiology in Tuberculosis Control. Her work integrates epidemiological research with policy, emphasizing practical applications of molecular tools and surveillance data. Notable contributions include analyzing TB strain diversity in public housing and modeling future TB trends in NYC. Publications highlight her expertise in tuberculosis epidemiology, SARS-CoV-2 variant analysis, and vaccine effectiveness in long-term care facilities. She has co-led emergency responses for Superstorm Sandy, Ebola, and the recent pandemic.

• Infectious Disease Epidemiology
• Molecular Epidemiology
• Tuberculosis Control
• +3 more

F. Felipe Suero, MD, is an Assistant Professor in the Department of Surgical Oncology at Temple University. He serves as Director of Perioperative Services at Fox Chase Cancer Center/TUH-Jeanes Campus and Chief of Anesthesiology at Temple University Hospital. His clinical expertise spans anesthesiology and thoracic surgery, with a focus on critical care interventions and pulmonary disease management. Temple University Fox Chase Cancer Center Department of Surgical Oncology Dr. Suero received his Doctor of Medicine from Cadiz Medical School (1970-1977), followed by doctoral courses at Autonoma Medical School in Madrid. He completed residencies in thoracic surgery (Hospital Fundacion Jimenez Diaz, Madrid), general surgery (Mercy Fitzgerald Hospital, Philadelphia), and anesthesiology (Cleveland Clinic). His research focuses on anesthesiological interventions in high-risk thoracic surgery, including chemical pleurodesis for pneumothorax, mediastinal fibrosis, and postoperative complications in lung cancer patients. Publications highlight innovative applications of pleurodesis and multidisciplinary approaches to thoracic pathologies. Key trends in his publications include: Chemical pleurodesis optimization for critical care Thoracic surgical complications in malignant lesions HIV-related pulmonary interventions Rare thoracic tumors (e.g., sternal chondrosarcoma) Infectious disease surgical complications (e.g., Mycobacterium chelonae) Dr. Suero has been recognized as a Top Doctor by Philadelphia Magazine (2024) and Delaware Daily Times (2015). His clinical work emphasizes perioperative care, surgical oncology, and Spanish-language medical services.

• Anesthesiology
• Thoracic Surgery
• Surgical Oncology
• +3 more

Marvin Meyers is a Professor of Chemistry and holds the Kranz Professorship for Excellence in Research at the School of Science and Engineering, Saint Louis University. He leads the Meyers Lab, focused on discovering novel drug candidates for neglected and infectious diseases, particularly antifungals and antiparasitics. His research integrates synthetic organic chemistry, medicinal chemistry, and structure-based drug design to optimize drug candidates' potency, pharmacokinetics, and safety. Educated at Dordt College (B.A., 1996) and the University of Illinois at Urbana-Champaign (Ph.D., 2000), Meyers teaches courses including CHEM 3100, CHEM 3970, and CHEM 4470/5470. His lab emphasizes undergraduate and graduate training in organic synthesis and drug discovery, with students contributing to publications and potential patent applications. Key research interests include drug repurposing (e.g., antifungal phenothiazines), antimalarial agents, and treatments for Cryptosporidium and hepatitis B virus. Collaborations with biologists and computational chemists drive discoveries in molecular pathways and drug targets. The lab's recent work includes antifungal mefloquine analogs (2024), fluorinated triazolopyridazines (2023), and HBV ribonuclease H inhibitors (2021). Meyers' lab is located in Monsanto Hall, and further details are available via www.meyerschemlab.com .

• Medicinal Chemistry
• Synthetic Organic Chemistry
• Chemical Biology
• +4 more

Shengyu Mu is an Associate Professor in the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences (UAMS) College of Medicine. His research focuses on the pathogenesis of hypertension and its progression to heart failure, with a particular emphasis on immune mechanisms in renal salt retention. Mu holds an M.D. from TianJin Medical University (2004) and a Ph.D. from the University of Tokyo (2011). His research portfolio includes NIH-funded projects investigating T cell homing to the kidney and immune memory in hypertension. Current grants span NIH-NHLBI (2R01 HL146713), American Heart Association (AHA23TPA1076467), and USDA-NIFA collaborations. Completed projects include studies on renal lymph-angiogenesis and macrophage metabolism in diabetes/tuberculosis comorbidity. Research areas integrate physiology, molecular genetics, and epigenetics to bridge basic science and clinical applications. The Mu Lab includes Assistant Professor Yunmeng Liu, Ph.D. candidates Christoph Mora and Kathrine Deck, and research team members recognized for awards like the AHA Predoctoral Fellowship and APS Research Recognition Awards. Key themes include CD8+ T cell activation, IFNγ signaling, and macrophage transition in hypertension pathogenesis.

• Hypertension
• Heart Failure Mechanisms
• Immune-Mediated Pathways in Cardiovascular Disease
• +4 more

Derek S. Tan is a Professor in the Department of Biochemistry and Biophysics at Weill Cornell Medical College, holding a Tri-Institutional Professor position effective from 2025. His research integrates chemical synthesis with biological applications, focusing on drug discovery, enzyme mechanisms, and therapeutic engineering. He maintains an active research program with continuous NIH funding. Education: Ph.D., Harvard University (2000) B.S., Stanford University (1995) Research Focus: Professor Tan's work spans chemical biology, medicinal chemistry, and microbiology. He designs bioactive molecules targeting bacterial permeability, enzyme inhibition, and cellular therapeutics. Key areas include ubiquitin pathway biochemistry, antibiotic development against Mycobacterium tuberculosis and Plasmodium falciparum , and engineered T-cell therapies for cancer. His interdisciplinary approach bridges synthetic chemistry with translational applications. Publication Trends: Recent articles (2021-2024) demonstrate three primary themes: 1) Development of mechanistic probes for enzyme systems (ubiquitin pathway, aminoacyl-tRNA synthetases), 2) Antibacterial/antiparasitic agent design leveraging bacterial permeability studies, and 3) Cellular engineering strategies including CAR-T micropharmacies for targeted drug activation. The work consistently combines synthetic chemistry innovation with biological validation. Grants: As Principal Investigator of the Tri-institutional PhD Program in Chemical Biology (NIH/NIGMS funded), he leads initiatives spanning 2020-2025 and 2025-2030. This underscores sustained commitment to interdisciplinary training at the chemistry-biology interface.

• Chemical Biology
• Medicinal Chemistry
• Biochemistry
• +3 more

Iwijn De Vlaminck is an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University. His research focuses on developing precision medicine technologies, including liquid biopsies for diagnosing infectious and immune-related diseases, and spatial profiling of microbiomes and host-microbiome interactions. He leads the De Vlaminck Lab, which integrates engineering, biophysics, and computational biology to advance diagnostics and therapeutics. Key affiliations include the College of Engineering and interdisciplinary graduate fields such as Biomedical and Biological Sciences and Computational Biology. Education: B.S., Electronic Engineering, Katholieke Universiteit Leuven (2000) M.S., Electronic Engineering, K.U. Leuven (2003) Ph.D., Science and Engineering, K.U. Leuven (2008) Research Interests: His lab develops high-throughput technologies for studying diseases like organ transplant rejection, urinary tract infections, and viral myocarditis. Innovations include spatial transcriptomics and methods to map microbial communities in tissues. Recent work addresses biomarkers for MIS-C in children and applications of cell-free DNA in spaceflight studies. Awards: NIH New Innovator Award (2017) Elected Fellow of the American Institute for Medical and Biological Engineering (2025) Rainin Foundation Synergy Award (2019) Teaching Excellence Awards (2017, 2022) Grants & Collaborations: Recipient of a $3M NSF grant for bio-inspired architecture and a $9.5M NIH grant for chronic fatigue syndrome research. Collaborates with institutions like Weill Cornell Medicine and NASA on spaceflight biology and clinical diagnostics. Labs & Teams: Directs the De Vlaminck Lab, which includes interdisciplinary researchers working on spatial omics, liquid biopsies, and microbiome technologies. Engaged in industry partnerships, including co-founding Kanvas Biosciences.

• Precision Medicine
• Liquid Biopsies
• Spatial Profiling of Microbiomes
• +7 more

Sarah A. Stanley is an Associate Professor in the Department of Immunology and Molecular Medicine at the School of Public Health. Her research focuses on understanding immune responses to Mycobacterium tuberculosis (Mtb), a pathogen responsible for significant global mortality. Her work addresses why natural immunity often fails to eradicate Mtb infections, exploring both host immune mechanisms and bacterial virulence strategies. The Stanley Lab employs a multidisciplinary approach, including bacterial/host genetics, microscopy, chemical biology, and proteomics to dissect host-pathogen interactions. Research interests include host-derived metabolites’ role in macrophage antimicrobial activity, Th17 immunity, bacterial nanocompartments as oxidative stress defenses, and human genetic polymorphisms influencing tuberculosis outcomes. Current projects investigate how interferon-γ-independent pathways and GM-CSF activation of HIF-1α modulate immunity, alongside bacterial strategies to evade host defenses. The lab also develops mucosal vaccination strategies using cyclic dinucleotide adjuvants to enhance T cell responses. Publications emphasize mechanisms of Mtb persistence, host immune evasion, and translational approaches to vaccine/therapeutic design. The lab’s long-term goals include identifying novel targets for therapies and vaccines to combat tuberculosis, leveraging insights from host-pathogen biology.

• Immunology
• Mycobacterium Tuberculosis
• Host-Pathogen Interactions
• +7 more

Tyler Bold, MD, PhD serves as Associate Professor in the Division of Infectious Diseases and International Medicine within the Department of Medicine at the University of Minnesota Medical School. He concurrently holds faculty appointments in the Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program and the Department of Medicine, establishing a multidisciplinary research presence spanning infectious disease pathogenesis, immunology, and host-pathogen interactions. His research program integrates clinical infectious disease expertise with fundamental immunological investigation, focusing on tuberculosis host-directed immunotherapy, SARS-CoV-2 pathogenesis mechanisms, and macrophage biology in atherosclerosis. Key interests include T cell costimulation in granulomatous diseases, viral-microbiome interactions during respiratory infections, and diagnostic innovations for resource-limited settings. His work bridges basic science discovery with translational clinical applications, particularly in immunocompromised populations and complex infectious syndromes. Analysis of his 15 most recent publications reveals dominant research trajectories in tuberculosis immunology (40% of articles), SARS-CoV-2 pathogenesis and therapeutics (35%), and atherosclerosis immunometabolism (15%), with emerging work on fungal infections in hematologic malignancies. The publications demonstrate consistent use of advanced techniques including single-cell resolution analysis, structural biology, and randomized clinical trials, reflecting both mechanistic depth and clinical relevance across infectious disease subspecialties.

• Infectious Diseases
• Immunology
• Microbiology
• +3 more

Joshua Warren is a Professor in the Department of Biostatistics at the Yale School of Public Health. He holds appointments in Climate Change and Health, Public Health Modeling, the Yale Superfund Research Center, and the Yale-BI Biomedical Data Science Fellowship. His academic journey includes a PhD in Statistics from North Carolina State University (2011), an MS from the same institution (2009), and a postdoctoral fellowship at UNC Chapel Hill (2014) before joining Yale. Warren's research focuses on developing hierarchical Bayesian methods for spatial and spatiotemporal data, assessing environmental exposures' impact on human health, and characterizing infectious disease spread. His work frequently involves introducing spatial and spatiotemporal models in Bayesian settings to study associations between environmental exposures like air pollution and health outcomes including preterm birth, low birth weight, and congenital anomalies. He also applies these methods in collaborative settings including epidemiology, geography, nutrition, and glaucoma research. His 15 most recent publications demonstrate extensive work at the intersection of environmental health, spatial statistics, and public health. The research spans air pollution health effects, tuberculosis transmission modeling, heat wave impacts on birth outcomes, and statistical methodology development. His work shows particular strength in applying Bayesian approaches to complex spatial and temporal data in public health contexts. Coauthor, Kenneth Rothman Epidemiology Prize Paper (2018) First Author, Best Paper in Biometrics (2012) Warren serves as Associate Editor for Statistics in Biosciences (2015-present) and previously for the Journal of the American Statistical Association (2018-2020). He has reviewed for the Health Effects Institute (2019), Swiss National Science Foundation (2017), and NIH study sections (2016). His collaborative network includes researchers like Nicole Deziel, Daniel Weinberger, Ted Cohen, and Xiaomei Ma. His laboratory focuses on statistical methods development with applications to public health problems, particularly those involving spatial and temporal data structures. Warren's work bridges theoretical statistics with practical public health applications, making significant contributions to how we understand environmental health risks and infectious disease dynamics.

• Spatial Statistics
• Spatiotemporal Modeling
• Bayesian Statistics
• +5 more

Anna Green is an Assistant Professor at the Manning College of Information & Computer Sciences (CICS) at the University of Massachusetts Amherst. She directs the Sequence Analysis and Genomics (SAGE) lab, which focuses on developing computational methods to understand genetic variation, with special emphasis on antibiotic-resistant bacteria. Her research integrates machine learning with genomic analysis to predict antibiotic resistance and understand its genetic basis. Education: Postdoctoral Fellow in Biomedical Informatics (2023) - Harvard Medical School PhD in Systems Biology (2019) - Harvard University BS in Molecular and Cell Biology (2013) - University of Connecticut Her research program at SAGE Lab focuses on: Applying machine learning to genomic sequences to predict antibiotic resistance Developing interpretable models of resistance mechanisms in bacteria Studying evolutionary patterns in Mycobacterium tuberculosis populations Discovering protein interactions through computational analysis of genomic sequences Building frameworks for coevolutionary sequence analysis Her recent publications demonstrate a consistent focus on antimicrobial resistance mechanisms in tuberculosis using cutting-edge computational approaches. Research spans machine learning applications, genomic dependency analysis, transcriptomic responses, and protein interaction mapping, consistently addressing public health challenges posed by evolving bacterial resistance. Dr. Green teaches several courses including: Introduction to Computational Biology and Bioinformatics (INFO 390C) Computational Biology and Bioinformatics (CS 690U) Machine learning on biological sequence data (CS 692X) She directs the SAGE Lab at UMass Amherst, where her team develops computational methods to combat antibiotic resistance through genomic analysis and predictive modeling.

• Computational Biology
• Machine Learning
• Antibiotic Resistance
• +3 more